TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02416791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be administered for 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational therapy will be administered for 40 minutes.
Study: NCT01159496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377 (SAM-760)
Description: Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
Study: NCT04117256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Current Stimulation
Description: 20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Current Stimulation
Description: 20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham DCS
Description: 20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham DCS
Description: 20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
Study: NCT03148301

Intervention type: OTHER
Intervention: Survey
Description: Survey
Study: NCT05736458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
Study: NCT01159496

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule, once daily for 14 days
Study: NCT02721238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% Albumin
Study: NCT00566215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal exclusion plus omentectomy
Description: Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal exclusion without omentectomy
Description: Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
Study: NCT02721238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte
Study: NCT04242927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid +Routine care
Description: Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routinely apply urea ointment and provide best supportive care.
Study: NCT01826591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Counseling/instruction on how to follow a low-carbohydrate diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet
Description: Counseling/instruction on how to follow a low-fat diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
Study: NCT01893151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iguratimod placebo
Description: Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
Study: NCT01826591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
Study: NCT00692172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: intramuscular injection (IM)
Study: NCT02359526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IlUVIEN
Description: All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
Study: NCT02869217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study: NCT02955992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving communication during the end-of-life process
Study: NCT01284725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil or azathioprine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunosuppressive treatment discontinuation
Study: NCT02006407

Intervention type: RADIATION
Group type: OTHER
Intervention: Cranial Radiotherapy
Description: Standard cranial radiotherapy administered dependent upon patient and brain tumor type.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI with Diffusion Tensor Imaging (DTI)
Description: Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuro-cognitive Testing (CogState)
Description: CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
Study: NCT02903316

Intervention type: PROCEDURE
Intervention: Fluids
Study: NCT03191019

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile-phone app for smoking cessation
Description: Android App for smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-phone app for smoking cessation
Description: Android App for smoking cessation
Study: NCT02869217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study: NCT05736458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High controllability TMS target
Description: Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High controllability TMS target
Description: Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
Study: NCT00355771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet OD in the morning for 8 weeks
Study: NCT03663699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: free access to the exergaming platform PlayPulse for 24 weeks
Study: NCT02411721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Intervention
Description: 1. Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~2. The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~3. Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination.
Study: NCT01914848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Care Planning ACP
Description: Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: A routine care discharge planning with the social service
Study: NCT04703881

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES ActaGain
Description: AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
Study: NCT00618657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT00727298

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
Study: NCT00618657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Optional correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Optional correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
Study: NCT02665000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Structured training programme
Description: Participants will undergo 5-days training sessions
Study: NCT03907501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: an herbal prebiotic plus probiotic
Study: NCT02685176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)
Description: A heater (STK Heatpac) will be used in the active warming arms of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No heat
Description: No active heating provided post cooling
Study: NCT03907501

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Triphala alone
Study: NCT00508235

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about the patient's relationship with their best friend.
Study: NCT01253876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy milk, Caw's milk
Study: NCT03907501

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert capsule
Study: NCT03326999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obturator nerve regional block
Description: Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Adductor canal regional block
Description: Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor canal regional block
Description: Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline as placebo comparator
Study: NCT01745861

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipidem (Omega-3 fish oil lipid emulsion)
Description: Lipidem 200 mg/ml daily infusion for 7 days maximum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lipofundin® MCT/LCT 20%
Description: Lipofundin® MCT/LCT 20% daily infusion for 7 days
Study: NCT04393545

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hallux valgus night splint
Description: The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
Study: NCT03043183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perioperational nutrition surpport
Description: Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
Study: NCT02216331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description.
Study: NCT04150250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iOWH032
Description: Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: V. cholerae Challenge
Description: Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V. cholerae Challenge
Description: Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotics
Description: Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)
Study: NCT02579941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling (pregnant)
Description: 5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM.
Study: NCT03889457

Intervention type: OTHER
Intervention: anticoagulation choice
Description: Type of anticoagulant chosen by the patient (oral or injectable).
Study: NCT04412876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine 30 mg qd
Study: NCT02327871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal cooling device (and usual standard procedure)
Description: Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
Study: NCT03029286

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Arm
Description: Health information provided by the American Cancer Society Website

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Web Intervention Arm
Description: Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
Study: NCT04473222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Well!
Description: Sleep Well! is a brief, behavioral sleep intervention. The intervention was originally comprised of healthy sleep advice and tested in the context of a sleep health education campaign for impoverished children. Based on preliminary research regarding the need for sleep intervention in primary care, Investigators have expanded the intervention to more comprehensively address poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Intervention components are based on effective pediatric behavioral sleep treatments.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep education
Description: Sleep education for caregivers of toddlers and preschoolers is provided via a Parent Family Education handout available to families and clinicians in the CHOP primary care network. The handout contains evidence-based advice about healthy sleep in early childhood.
Study: NCT01210560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan IR
Description: 90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
Study: NCT01769573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG-HRV16
Description: A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
Study: NCT04412876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Imipramine 25mg qd